Dr. Reddy’s, Vivus settle long-pending patent litigation for Qsymia

01 Sep 2017 Evaluate

Dr. Reddy’s Laboratories and Nasdaq-listed Vivus Inc. have entered into settlement agreement to resolve a long-pending patent litigation related to weight management capsule Qsymia.

The settlement permits the Hyderabad-based drugmaker to begin selling a generic version of Qsymia from June 2025, or earlier under certain circumstances. In the event of an early launch, Vivus will receive a royalty on sales of the generic version of the drug.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.



Dr. Reddys Lab Share Price

1275.00 -5.40 (-0.42%)
16-Dec-2025 11:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1788.20
Dr. Reddys Lab 1275.00
Cipla 1506.60
Zydus Lifesciences 922.05
Lupin 2091.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×